A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional ...

More information: Torben Schiffner et al, Vaccination induces broadly neutralizing antibody precursors to HIV gp41, Nature Immunology (2024). DOI: 10.1038/s41590-024-01833-w ...

The VELs confront the enormous variability of pathogens such as HIV, hepatitis, influenza, malaria, dengue and cancer. Therefore, the proposal of the research group is "a new concept of vaccines ...

Therefore, we were extremely excited to work with the UNC team to adapt this virus-specific T-cell-therapy approach to the HIV setting." In the small proof-of-concept study, Margolis, Bollard ...

"Our proof-of-concept animal studies demonstrate a step forward in the fight against this virus, bringing us closer to innovative and potentially transformative therapies for HIV patients," said ...

Researchers conducted a breakthrough proof-of-concept study that found an HIV-like virus particle that could cease the need for lifelong medications. Researchers in George Mason University's ...

Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness. £5 allows us to reach millions of people globally with accurate and reliable ...

When the HIV/AIDS crisis emerged in the 1980s ... they also redefined the concept of family. Artifacts and stories from such organizations as God’s Love We Deliver, which began when a hospice ...

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV ...

A new map shows the highest rates of HIV for gay, bisexual men. — -- A map documenting HIV rates for gay and bisexual men has revealed they are most at risk for becoming infected in multiple ...

"These trials provide proof of concept for a stepwise approach to elicit custom-tailored responses -- not just for our vaccine, but for the vaccine field at large, including non-HIV vaccines." ...